HESI Emerging Issues Process
2012 Prioritization of New Topics: Survey Form
Please complete the first page of this form and return by 16 July 2012 to:
Ms. Cyndi Nobles (HESI), cnobles@hesiglobal.org, Fax: 202-659-3617
Name: _______________________
Affiliation: ______________________
Phone: ______________________
Email: _________________________
Background: In the fall of 2011, HESI conducted its annual survey for emerging scientific issues.
From this survey, the HESI Emerging Issues Committee (EIC*) selected two topics for
consideration in 2012 based on fulfillment of one or more of the following criteria:

Basic science issues related to safety assessment.

Emerging methods and technologies with applications to safety assessment.

Regulatory initiatives, current industry concerns and/or significant public health issues with
opportunity for scientific input.
Goal: The goal of the Emerging Issues (EI) Process is to select one topic for HESI action in the
fall of 2012.
New Topics: The following topics were presented for consideration at the June 2012 HESI Annual
Meeting in Prague, Czech Republic. Please indicate your level of enthusiasm for each topic
by assigning a priority score (1, 2, 3). NOTE: Scoring is explained on the next page and
reflects your organization’s current interest level. It does not necessarily represent a
commitment to participate should the topic go forward.
Score
Topics for Consideration in 2012
_____
The utilization of dried blood spot to reduce animal usage in
non-clinical studies
_____
Translational safety biomarker assessment of neurotoxicity
*2011-2012 EIC: Drs. Cynthia Afshari (Amgen Inc.), Robert Barter (ExxonMobil Biomedical Sciences),
Karen Blackburn (The Procter and Gamble Company), Werner Bomann (Bayer CropScience), Darlene Dixon
(National Institute of Environmental Health Sciences), B. Bhaskar Gollapudi (The Dow Chemical Company),
Jesse Goodman (US Food and Drug Administration), George Gray (George Washington University), Patrick
Guiney (SC Johnson & Son, Inc.), Toshihisa Ishikawa (RIKEN Yokohama Institute), Ian Kimber (University of
Manchester), James Klaunig (Indiana University), Derek Muir (Environment Canada), Stephen Newsholme
(GlaxoSmithKline), George Pugh (The Coca-Cola Company), Mark Tirmenstein (Bristol-Myers Squibb), Gary
Williams (New York Medical College), and Hal Zenick (US Environmental Protection Agency).
HESI Emerging Issues Process
2012 Prioritization of New Topics
Page 2
EXPLANATION OF SCORING:
Level of interest:
LOW
MEDIUM
HIGH
▬▬▬▬▬▬▬▬▬▬▬▬▬
Priority Score:
1
2
3
HIGH = My organization would be willing to commit resources (i.e., “sweat equity” and/or
financial support) for this project.
MEDIUM = My organization may be willing to commit resources to support this project.
LOW = My organization is not likely to commit resources for this project.
Past experience with the HESI EI Process indicates that a topic with the best chance of
developing into a successful program / project possesses some or all of the following
characteristics:

The topic identifies an issue with the potential to be resolved.

The topic presents an issue that is best resolved through tripartite partnerships among
scientists from government, academia and industry.

The topic provides a foundation for developing sound science for emerging regulatory and
public health issues.

The topic provides an opportunity to make significant contributions on an international
level.
If you have questions or comments about the specific topics being considered in 2012 and/or the
HESI Emerging Issues Process in general, please contact:
Nancy G. Doerrer, MS
HESI Associate Director
202-659-3306 (ext 116)
ndoerrer@hesiglobal.org
Please complete the first page of this form
and return by 16 July 2012 to:
Ms. Cyndi Nobles
Fax: 202-659-3617
cnobles@hesiglobal.org